
CORRIGENDUM

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Danny N. Khalil, Eric L. Smith, Renier J. Brentjens and Jedd D. Wolchok

Nature Reviews Clinical Oncology **13**, 273–290 (2016)

In the sentence “Results of a phase I trial¹¹³ demonstrated that an agonist mAb targeting CD40 given as monotherapy has antitumour activity in patients with melanoma or RCC”, CD40 should have read OX40. This error has been corrected in the online HTML and PDF versions of the article.